Amgen Inc.

Filing receipts

“39 Nonoperating expenses/income and income taxes Nonoperating expenses/income and income taxes were as follows (dollar amounts in millions): Three months ended March 31, 2026 2025 Interest expense, net $ (657) $ (723) Other income, net $ 75 $ 1,518 Provision for income taxes $ 265 $ 243 Effective tax rate 12.7 % 12.3 % Interest expense, net Interest expense, net, decreased for the three months ended March 31, 2026, primarily due to lower average debt outstanding driven by deleveraging in 2025 and, to a lesser extent, lower weighted-average fixed and floating interest rates on the debt.”

“Investing Cash used in investing activities during the three months ended March 31, 2026 and 2025, was primarily due to capital expenditures of $712 million and $411 million, respectively, including construction costs for new plants and expansion of manufacturing capacity.”

“35 ENBREL Total ENBREL sales by geographic region were as follows (dollar amounts in millions): Three months ended March 31, 2026 2025 Change ENBREL — U.S. $ 314 $ 504 (38) % ENBREL — Canada 6 6 — % Total ENBREL $ 320 $ 510 (37) % The decrease in ENBREL sales for the three months ended March 31, 2026 was primarily driven by unfavorable changes to estimated sales deductions of 18% and lower net selling price of 15% resulting from the impact of U.S.”